CROI
<ѻý class="page-description">Conference on Retroviruses and Opportunistic Infectionsѻý>Questionable efficacy, potential toxicity "tips the scales" against clofazimine-based regimen
Virologic suppression rate was 94.2% in both groups
Three-drug combo over 4 months was comparable to standard treatment over 6 months
Trial halted early for efficacy despite not meeting significance criteria on primary endpoint
Weekly injections reduced liver fat by 31% at 6 months
Lowering blood pressure, cholesterol prove feasible in randomized trials
Fixed-dose combination shows promise in small trial
Unsanitary conditions resulted in infections in three people; investigation still ongoing
Levels of IL-6, high-sensitivity CRP, and soluble CD163 were decreased with the GLP-1 agonist
Other data showed high uptake of doxycycline post-exposure prophylaxis among PrEP users
Trial is "essential first step" in exploring this public health strategy, researcher says
Main focus now will be approaches using broadly neutralizing HIV-1 antibodies, researchers say
Antiviral should have been recommended sooner for non-ventilated patients, editorialist argues
Trial shows noninferiority to daily antiretroviral pills for controlling HIV
-
IDWeek: A Joint Meeting of IDSA, SHEA, HIVMA, PIDS, and SIDP
October 2024
-
CROI: Conference on Retroviruses and Opportunistic Infections
March 2024
-
ASTMH: American Society of Tropical Medicine & Hygiene
October 2022
-
IDWeek Podcast: Podcast from the Joint Meeting of IDSA, SHEA, HIVMA, and PIDS
October 2020